A multicentre, randomized, double-blind, placebo-controlled, parallel-design trial of the efficacy and safety of subcutaneous tetrodotoxin (Tectin) for moderate to severe inadequately controlled cancer-related pain.

Trial Profile

A multicentre, randomized, double-blind, placebo-controlled, parallel-design trial of the efficacy and safety of subcutaneous tetrodotoxin (Tectin) for moderate to severe inadequately controlled cancer-related pain.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 08 Apr 2008

At a glance

  • Drugs Tetrodotoxin (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Acronyms TTX
  • Sponsors WEX Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2008 A reanalysis was published in the April 2008 issue of the Journal of Pain and Symptom Management; based on this, a new trial [TEC-006; see 700032511] has been initiated.
    • 12 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top